Literature DB >> 33633669

Elevated Creatinine Kinase in Peripheral Neuropathy Is Associated With Muscle Cramping.

Allison Jordan1, Arun Nagaraj1, J Chad Hoyle1, Amro Maher Stino1, W David Arnold1, Bakri Elsheikh1.   

Abstract

Introduction: Serum Creatinine Kinase (CK) is a non-specific marker of muscle damage. There has been limited investigation of the association between peripheral neuropathy and CK elevation (hyperCKemia).
Methods: We performed a chart review to investigate the CK level in peripheral neuropathies. Demographics, clinical history, physical exam, electrodiagnostic data, CK level, statin use, etiology of neuropathy, and concomitant neuromuscular disorders were recorded. HyperCKemia was defined using our laboratory cutoff values of >180 U/L (women) and >220 U/L (men).
Results: We identified 450 patients with peripheral neuropathy who had CK testing, 92 (20.4%) of whom had hyperCKemia. Sixty-one of those patients (13.5% of the total figure) had a concomitant etiology that could explain the CK elevation. Thirty-one patients (6.9%) had no other identifiable etiology for their hyperCKemia beyond the neuropathy. The average CK level in the latter cohort with hyperCKemia was 376 U/L (women: 312 U/L; men: 444 U/L). The frequency of cramping was greater in patients with elevated vs. normal CK (p < 0.0001). Discussion: HyperCKemia can occur in patients with peripheral neuropathy and appears to associate with cramping.
Copyright © 2021 Jordan, Nagaraj, Hoyle, Stino, Arnold and Elsheikh.

Entities:  

Keywords:  CK; cramping; muscle enzyme; neuropathy; peripheral neuropathy

Year:  2021        PMID: 33633669      PMCID: PMC7902013          DOI: 10.3389/fneur.2021.613599

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  21 in total

1.  A case of CMT 1B due to Val 102/fs null mutation of the MPZ gene presenting as hyperCKemia.

Authors:  M Luigetti; A Modoni; R Renna; G Silvestri; E Ricci; N Montano; G Tasca; M Papacci; M Monforte; A Conte; M G Pomponi; M Sabatelli
Journal:  Clin Neurol Neurosurg       Date:  2010-05-26       Impact factor: 1.876

2.  Frequent laboratory abnormalities in CIDP patients.

Authors:  Alon Abraham; Hana Albulaihe; Majed Alabdali; Mohammad Qrimli; Ari Breiner; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril
Journal:  Muscle Nerve       Date:  2016-05-09       Impact factor: 3.217

3.  Peripheral neuropathy associated with hereditary and sporadic inclusion body myositis: confirmation by electron microscopy and morphometry.

Authors:  B Hermanns; M Molnar; J M Schröder
Journal:  J Neurol Sci       Date:  2000-10-01       Impact factor: 3.181

4.  EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia.

Authors:  T Kyriakides; C Angelini; J Schaefer; S Sacconi; G Siciliano; J J Vilchez; D Hilton-Jones
Journal:  Eur J Neurol       Date:  2010-04-05       Impact factor: 6.089

5.  Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study.

Authors:  J L Joy; S J Oh
Journal:  Muscle Nerve       Date:  1989-03       Impact factor: 3.217

6.  Pain in Guillain-Barré syndrome.

Authors:  A H Ropper; B T Shahani
Journal:  Arch Neurol       Date:  1984-05

7.  Natural history of muscle cramps in amyotrophic lateral sclerosis.

Authors:  James B Caress; Stephanie L Ciarlone; Elizabeth A Sullivan; Leah P Griffin; Michael S Cartwright
Journal:  Muscle Nerve       Date:  2015-09-28       Impact factor: 3.217

8.  Characteristics of muscle cramps in patients with polyneuropathy.

Authors:  Sarah K Maxwell; Seint Kokokyi; Ari Breiner; Hamid Ebadi; Vera Bril; Hans D Katzberg
Journal:  Neuromuscul Disord       Date:  2014-05-09       Impact factor: 4.296

9.  Cramps and small-fiber neuropathy.

Authors:  Glenn Lopate; Elizabeth Streif; Matthew Harms; Christopher Weihl; Alan Pestronk
Journal:  Muscle Nerve       Date:  2013-06-28       Impact factor: 3.217

10.  Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis.

Authors:  M K Rafiq; E Lee; M Bradburn; C J McDermott; P J Shaw
Journal:  Eur J Neurol       Date:  2016-03-31       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.